A PHASE 1, OPEN LABEL, 2-PERIOD, FIXED SEQUENCE, STUDY TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY OF 14C PF 06826647 IN HEALTHY MALE PARTICIPANTS
Latest Information Update: 22 Feb 2021
At a glance
- Drugs Ropsacitinib (Primary) ; Ropsacitinib (Primary)
- Indications Hidradenitis suppurativa; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 17 Feb 2021 Status changed from recruiting to completed.
- 22 Dec 2020 Status changed from not yet recruiting to recruiting.
- 22 Oct 2020 New trial record